[
  {
    "uuid": "c889219a67a7716940ba931d9cc95e1e962dab0a",
    "url": "https://diariocorreo.pe/deportes/minsa-informa-que-hugo-sotil-permanece-internado-en-uci-bajo-monitoreo-constante-peru-noticia",
    "ord_in_thread": 0,
    "parent_url": null,
    "author": "Redacción Correo",
    "published": "2024-12-20T01:25:00Z",
    "title": "Minsa informa que Hugo Sotil permanece internado en UCI bajo monitoreo constante",
    "text": "El Ministerio de Salud (Minsa) reportó que Hugo Sotil, exjugador de la selección peruana y destacado ídolo del fútbol, se encuentra internado en la Unidad de Cuidados Intensivos (UCI) del Hospital Dos de Mayo.\nSotil, quien celebró una exitosa carrera en equipos como Deportivo Municipal, Alianza Lima y Barcelona de España, fue ingresado de emergencia durante la madrugada del jueves, debido a complicaciones en su estado de salud.\nEl exmundialista, de 75 años, fue recibido en el Servicio de Emergencia del hospital, donde recibió atención especializada inmediata. Posteriormente, debido a la gravedad de su condición, fue trasladado a la UCI, donde permanece bajo monitoreo constante por parte del equipo médico.\nA través de un comunicado oficial, el Minsa indicó que, por solicitud de la familia de Sotil, no se brindarán más detalles sobre su estado de salud. Además, hizo un llamado a los medios de comunicación y al público en general para respetar la privacidad del exfutbolista y su entorno cercano durante este momento delicado.\nEl Ministerio también garantizó que el Hospital Dos de Mayo está proporcionando toda la atención médica especializada que Sotil necesita en estos momentos críticos.\nSotil, apodado cariñosamente como el ‘Cholo’, dejó una huella imborrable en el fútbol peruano y mundial. Su participación en los Mundiales de México 1970 y Argentina 1978, así como su destacada actuación en la Copa América de 1975, lo convierten en una de las figuras más queridas y respetadas en la historia del deporte nacional.\nTE PUEDE INTERESAR\n[Congreso cita al ministro del Interior por retiro de financiamiento británico a la Dirandro](https://diariocorreo.pe/politica/congreso-cita-al-ministro-del-interior-por-retiro-de-financiamiento-britanico-a-la-dirandro-peru-mininter-juan-jose-santivanez-noticia/) [Waldemar Cerrón apoya a su hermano Vladimir tras decisión del TC: “Hasta más allá de la victoria”](https://diariocorreo.pe/politica/waldemar-cerron-apoya-a-su-hermano-vladimir-tras-decision-del-tc-hasta-mas-alla-de-la-victoria-peru-caso-aerodromo-wanka-noticia/) [Rafael López Aliaga propone referéndum sobre pena de muerte para delitos graves](https://diariocorreo.pe/politica/rafael-lopez-aliaga-propone-referendum-sobre-pena-de-muerte-para-delitos-graves-peru-noticia/) [Ruth Luque solicita comisión para investigar la presunta red de prostitución en el Congreso](https://diariocorreo.pe/politica/ruth-luque-solicita-comision-para-investigar-la-presunta-red-de-prostitucion-en-el-congreso-peru-mesa-directiva-noticia/) [Dina Boluarte sobre 3% de aprobación en encuestas: “No estamos trabajando para ser artistas de Hollywood”](https://diariocorreo.pe/politica/dina-boluarte-sobre-3-de-aprobacion-en-encuestas-no-estamos-trabajando-para-ser-artistas-de-hollywood-pnp-inseguridad-noticia/)",
    "highlightText": "",
    "highlightTitle": "",
    "highlightThreadTitle": "",
    "language": "spanish",
    "sentiment": "negative",
    "categories": [
      "Health"
    ],
    "topics": [
      "Health->medical condition",
      "Health->health care approach"
    ],
    "ai_allow": true,
    "has_canonical": false,
    "webz_reporter": false,
    "external_links": [],
    "external_images": [],
    "entities": {
      "persons": [
        {
          "name": "Hugo Sotil",
          "sentiment": "negative"
        }
      ],
      "organizations": [
        {
          "name": "Minsa",
          "sentiment": "negative"
        },
        {
          "name": "Ministerio de Salud",
          "sentiment": "negative"
        },
        {
          "name": "Unidad de Cuidados Intensivos",
          "sentiment": "none"
        },
        {
          "name": "UCI",
          "sentiment": "none"
        }
      ],
      "locations": []
    },
    "syndication": {
      "syndicated": null,
      "syndicate_id": null,
      "first_syndicated": false
    },
    "rating": null,
    "crawled": "2024-12-20T03:37:34.382+02:00",
    "updated": "2024-12-20T03:37:34.382+02:00"
  },
  {
    "uuid": "1f1eaf09f6c66952a5589df12c52991a372e846e",
    "url": "https://wach.com/news/local/sc-medicaid-patients-face-uncertainty-as-state-challenges-planned-parenthood-funding",
    "ord_in_thread": 0,
    "parent_url": null,
    "author": "Meghan Gonyo",
    "published": "2024-12-19T21:35:00Z",
    "title": "SC Medicaid patients face uncertainty as state challenges Planned Parenthood funding",
    "text": "Columbia, S.C. (WACH) — Wednesday, the U.S. Supreme Court announcing they will review South Carolina’s effort to defund Planned Parenthood (PPSA).\nEver since Planned Parenthood South Atlantic patient Julie Edwards, filed a lawsuit in 2018, the U.S. District court has permanently blocked Governor McMaster's executive order. That allows South Carolina patients enrolled in Medicaid to continue receiving care from the facilities.\nThe order issued by the Governor in 2018, attempted to prevent people enrolled in Medicaid programs from accessing preventative care at Planned Parenthood South Atlantic health centers in Charleston and Columbia.\nSouth Carolina is one of dozens of states that have passed laws restricting access to abortion after the supreme court overturned Roe v. Wade in 2022.\nFederal law prohibits states from interfering with Medicaid patients’ access, giving them the right to visit any qualified family provider that accepts Medicaid, including those that provide abortion like PPSA.\nSouth Carolina is now asking judges to review their decision to block funding to planned parenthood for the third time\nIn a statement, PPSA President, Jenny Black said:\nThis case is politics at its worst: Anti-abortion politicians using their power to target planned parenthood and block people who use Medicaid as their primary form of insurance from getting essential health care like cancer screenings and birth control.\nGovernor Henry McMaster this week, saying he’s “confident” the U.S. Supreme Court will side with him this time around. McMaster saying taxpayer dollar should never fund abortion providers like Planned Parenthood.\nAccess to abortion has led to rallies at the state house since Roe v. Wade was overturned as South Carolina lawmakers then took on this issue themselves.\nCurrent state law prohibits abortion at the six week of a pregnancy or as soon as a fetal heartbeat can be detected with exceptions in cases of rape, incest or health of the mother.\nSeveral states have also enacted laws blocking planned parenthood from receiving Medicaid funding,\nPPSA said in a statement that they continue to be a South Carolina Medicaid provider as this case moves forward.",
    "highlightText": "",
    "highlightTitle": "",
    "highlightThreadTitle": "",
    "language": "english",
    "sentiment": "negative",
    "categories": [
      "Politics",
      "Health",
      "Social Issue"
    ],
    "topics": [
      "Politics->fundamental rights",
      "Politics->healthcare policy",
      "Health->health organisation",
      "Social Issue->social services",
      "Social Issue->discrimination"
    ],
    "ai_allow": true,
    "has_canonical": false,
    "webz_reporter": false,
    "external_links": [],
    "external_images": [],
    "entities": {
      "persons": [
        {
          "name": "Julie Edwards",
          "sentiment": "none"
        },
        {
          "name": "McMaster",
          "sentiment": "none"
        }
      ],
      "organizations": [
        {
          "name": "SC Medicaid",
          "sentiment": "negative"
        },
        {
          "name": "U.S. Supreme Court",
          "sentiment": "negative"
        }
      ],
      "locations": []
    },
    "syndication": {
      "syndicated": false,
      "syndicate_id": "1f1eaf09f6c66952a5589df12c52991a372e846e",
      "first_syndicated": true
    },
    "rating": null,
    "crawled": "2024-12-20T00:50:10.148+02:00",
    "updated": "2024-12-20T00:50:10.148+02:00"
  },
  {
    "uuid": "8c0807d3676db0f73f5fa0eaaf53343386db5c20",
    "url": "https://siviaggia.it/varie/aereo-come-vestirsi/514848",
    "ord_in_thread": 0,
    "parent_url": null,
    "author": "priscillapiazza",
    "published": "2025-01-30T12:30:00Z",
    "title": "Misure più severe a bordo degli aerei: attenzione al dress code",
    "text": "Le compagnie aeree sono sempre più attente all’ abbigliamento dei passeggeri , con nuove regole in vigore che vietano abiti considerati inappropriati durante un volo. Spirit Airlines ad esempio, compagnia statunitense, ha recentemente annunciato misure più severe dopo aver registrato diversi episodi di outfit inadeguati a bordo.\nMa non è la sola: anche altri vettori hanno regole simili e alcune compagnie europee sembrano seguire lo stesso esempio. Vediamo più nel dettaglio quale sarebbe l’abbigliamento più consono a un viaggio in aereo e cosa si rischia se si viola il dresscode delle compagnie aeree che hanno a cuore la questione.\nLe regole sul vestiario in volo delle compagnie aeree Lo scorso gennaio, Spirit Airlines ha aggiornato il suo “Contratto di Carriage” imponendo un divieto sui passeggeri che indossano abiti non adeguati. Tra le nuove disposizioni, figurano il divieto di volare senza scarpe (a piedi nudi) e l’uso di vestiti che possano essere considerati “inadeguati”, come abiti trasparenti , abbigliamento che non copre adeguatamente il corpo, e, ovviamente, t-shirt con scritte oscene . La compagnia ha dichiarato che tali regole sono state introdotte dopo che alcuni passeggeri hanno cercato di imbarcarsi con outfit discutibili, come top corti o t-shirt con slogan volgari. La nuova politica non si limita all’abbigliamento: è previsto anche il divieto di body art (tatuaggi, piercing) che siano “osceni o offensivi”.\nAnche altre compagnie aeree operative oggi negli Stati Uniti, come United Airlines e Delta Air Lines , hanno politiche simili a quelle di Spirit Airlines. United Airlines, ad esempio, ha dichiarato che i passeggeri possono essere rifiutati se sono a piedi nudi, indossano abiti “non appropriati” o “osceni”. Delta Air Lines avverte che se l’abbigliamento, l’atteggiamento o l’igiene di un passeggero creano un “rischio di offesa o disagio” per gli altri passeggeri, questi possono essere rimossi dal volo.\nSebbene le regole siano chiaramente esplicitate da alcune compagnie statunitensi, non tutte le linee aeree sono altrettanto trasparenti. Alcuni vettori europei, tra cui Jet2 , Ryanair , TUI ed EasyJet , pur non avendo linee guida ufficiali pubblicate sui loro siti web, applicano regole simili in fase di imbarco.\nNon a caso, un membro dell’equipaggio di una nota compagnia europea ha recentemente dichiarato che è assolutamente legittimo impedire l’imbarco a chi non rispetta un abbigliamento accettabile, ad esempio a chi indossa t-shirt con parolacce o loghi offensivi.\nCosa succede se non ci si veste in modo appropriato in aereo? Le compagnie aeree, sia negli Stati Uniti che in Europa, sottolineano che il rispetto delle regole di abbigliamento non è solo una questione di ordine, ma di rispetto per gli altri passeggeri e per l’esperienza complessiva del volo. Il rischio di imbarcarsi con abiti inappropriati include il rifiuto di accesso al volo , con il passeggero costretto a cambiare abbigliamento o a scegliere un altro volo.\nSebbene queste regole possano sembrare eccessive per alcuni, le compagnie aeree oggi sono davvero sempre più decise a mantenere l’ambiente a bordo confortevole per tutti, riducendo i potenziali disagi che derivano da abbigliamento inadeguato o comportamenti problematici da parte dei passeggeri in volo.",
    "highlightText": "",
    "highlightTitle": "",
    "highlightThreadTitle": "",
    "language": "italian",
    "sentiment": "negative",
    "categories": [
      "Lifestyle and Leisure",
      "Social Issue",
      "Human Interest"
    ],
    "topics": [
      "Lifestyle and Leisure->lifestyle",
      "Social Issue->social condition"
    ],
    "ai_allow": true,
    "has_canonical": false,
    "breaking": false,
    "webz_reporter": false,
    "external_links": [],
    "external_images": [],
    "entities": {
      "persons": [],
      "organizations": [],
      "locations": []
    },
    "syndication": {
      "syndicated": null,
      "syndicate_id": null,
      "first_syndicated": false
    },
    "trust": null,
    "rating": null,
    "crawled": "2025-01-31T06:55:22.811+02:00",
    "updated": "2025-01-31T06:55:22.811+02:00"
  },
  {
    "uuid": "3c7ed5f0351081e875748a8a5a152229f5e74671",
    "url": "https://www.punto-informatico.it/boom-ricerche-google-cancellare-facebook-instagram",
    "ord_in_thread": 0,
    "parent_url": null,
    "author": "Tiziana Foglio",
    "published": "2025-01-10T07:05:00Z",
    "title": "Boom di ricerche su Google per cancellare Facebook e Instagram",
    "text": "C’è aria di rivolta contro Meta , e si vede anche su Google. Da quando Mark Zuckerberg ha annunciato che l’azienda metterà fine al sistema di fact-checking esterno , allenterà le politiche di moderazione dei contenuti e toglierà i limiti ai post politici nei feed degli utenti, le ricerche su come eliminare gli account di Facebook , Instagram e Threads sono schizzate alle stelle negli Stati Uniti.\nMeta elimina fact-checking, boom di ricerche per chiudere account Facebook, Instagram e Threads Molti vedono la decisione di Meta come un tentativo di compiacere la nuova amministrazione Trump ed evitare ritorsioni politiche. Ma le conseguenze potrebbero essere serie: senza filtri, post offensivi , discorsi violenti e disinformazione potrebbero diffondersi ancora più rapidamente sulle piattaforme di Zuckerberg.\nLa reazione non si è fatta attendere. L’interesse per le ricerche su come abbandonare le piattaforme di Meta è esploso questa settimana, soprattutto negli ultimi due giorni. Termini come “ come cancellare definitivamente facebook ” hanno raggiunto il punteggio massimo di 100 su Google Trends, il livello più alto possibile.\nAltre ricerche correlate, quali “ come eliminare tutte le foto da facebook “, “ alternative a facebook “, “ come uscire da facebook “, “ come eliminare l’account threads ” e “ come eliminare l’account instagram senza fare il login “, sono diventate virali, con un aumento di popolarità di oltre il 5000% rispetto ai periodi precedenti.\nIl rischio di ripetere gli errori del passato Questa esplosione di ricerche sottolinea il timore che Meta possa ripetere gli errori del passato. L’azienda aveva introdotto il fact-checking e la moderazione dei contenuti dopo anni in cui disinformazione e incitamenti alla violenza avevano proliferato sulle sue piattaforme, causando danni nel mondo reale.\nL’esempio più eclatante è il tentativo di insurrezione a Capitol Hill del 6 gennaio 2021, alimentato da appelli alla violenza coordinati su Facebook e Instagram. O al genocidio dei Rohingya in Myanmar, incitato anche attraverso le piattaforme di Meta. Nel 2021, lo stesso Zuckerberg aveva riconosciuto che la comunità di Meta non voleva che la politica e le liti invadessero la loro esperienza sui social.\nOra però fa marcia indietro, parafrasando i commenti di Elon Musk su X sulla libertà di espressione. Meta sostituirà i fact-checker esterni con un sistema di “ note della comunità ” simile a quello di X, in cui gli utenti possono segnalare i post che secondo loro hanno bisogno di più contesto.\nLa corsa alle alternative decentralizzate Ma mentre Meta allenta la presa, gli utenti cercano alternative. Nello stesso periodo, sono schizzate anche le ricerche per “ alternative a facebook ” e per piattaforme decentralizzate come Bluesky e Mastodon , che stanno guadagnando popolarità da quando Elon Musk ha rilevato Twitter.\nIl CEO di Mastodon, Eugen Rochko, ha criticato duramente i cambiamenti di Meta, definendoli “una preoccupazione per chiunque abbia una coscienza “. Ha anche avvertito che gli utenti che condividono post da Threads a Mastodon saranno monitorati per evitare discorsi d’odio e violazioni delle policy della piattaforma.\nE ora che si fa? Insomma, la decisione di Meta di allentare le maglie del fact-checking e della moderazione sta sollevando un polverone. E spinge molti utenti a chiedersi se sia ancora etico restare sulle sue piattaforme o se sia il momento di cercare alternative più responsabili. Certo, cancellare un account social non è una scelta facile, soprattutto se lì abbiamo costruito relazioni e comunità importanti. Ma di fronte al rischio di un’ulteriore esplosione di odio e disinformazione, forse è una scelta necessaria.",
    "highlightText": "",
    "highlightTitle": "",
    "highlightThreadTitle": "",
    "language": "italian",
    "sentiment": "negative",
    "categories": [
      "Social Issue",
      "Economy, Business and Finance",
      "Science and Technology"
    ],
    "topics": [
      "Social Issue->discrimination",
      "Social Issue->social networking",
      "Economy, Business and Finance->business governance",
      "Science and Technology->technology and engineering",
      "Science and Technology->social sciences"
    ],
    "ai_allow": true,
    "has_canonical": false,
    "breaking": null,
    "webz_reporter": false,
    "external_links": [
      "https://www.washingtonpost.com/technology/2021/10/22/jan-6-capitol-riot-facebook/",
      "https://washingtonpost.com/technology/2021/10/22/jan-6-capitol-riot-facebook/",
      "https://www.washingtonpost.com/technology/2021/10/22/jan-6-capitol-riot-facebook"
    ],
    "external_images": [],
    "entities": {
      "persons": [
        {
          "name": "Mark Zuckerberg",
          "sentiment": "neutral"
        },
        {
          "name": " Trum",
          "sentiment": "none"
        }
      ],
      "organizations": [
        {
          "name": "Google",
          "sentiment": "negative"
        },
        {
          "name": " Thread",
          "sentiment": "none"
        }
      ],
      "locations": [
        {
          "name": " Stati Unit",
          "sentiment": "none"
        }
      ]
    },
    "syndication": {
      "syndicated": null,
      "syndicate_id": null,
      "first_syndicated": false
    },
    "rating": null,
    "crawled": "2025-01-10T12:07:40.351+02:00",
    "updated": "2025-01-10T12:07:40.351+02:00"
  },
  {
    "uuid": "ff17f08e0724799d616136ebf1140ab65a9218fb",
    "url": "https://www.finanzen.net/nachricht/aktien/seven-oral-presentations-innovent-to-present-breakthrough-clinical-data-of-ibi363-pd-1-il-2%CE%B1-bias-and-other-novel-drug-candidates-at-the-2025-asco-annual-meeting-14415046",
    "ord_in_thread": 0,
    "author": "Importer",
    "published": "2025-04-23T23:00:00Z",
    "title": "Seven Oral Presentations: Innovent to Present Breakthrough Clinical Data of IBI363（PD-1/IL-2α-bias）and Other Novel Drug Candidates at the 2025 ASCO Annual Meeting | finanzen.net",
    "text": "Home Aktien Seven Oral Presentations: Innovent to Present Breakthrough Clinical Data of IBI363（PD-1/IL-2α-bias）and Other Novel Drug Candidates at the 2025 ASCO Annual Meeting Die Top 10 Coins im Depot - mit dem finanzen.net Top 10 Crypto ETP. Jetzt informieren! Seven Oral Presentations: Innovent to Present Breakthrough Clinical Data of IBI363（PD-1/IL-2α-bias）and Other Novel Drug Candidates at the 2025 ASCO Annual Meeting 24.04.25 01:00 Uhr Werbung SAN FRANCISCO and SUZHOU,China , April 24, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (\"Innovent\") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that clinical data for its innovative bispecific antibodies and ADC molecules, including oral presentations for IBI363 (PD-1/IL-2 α -bias ) and IBI343 (CLDN18.2 ADC), will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2025 from May 30 to June 3, 2024 , in Chicago, Illinois , U.S.\nDr. Hui Zhou , Senior Vice President of Innovent, stated: \"We are delighted to announce that at 2025 ASCO Annual Meeting, the first wave of three indications under development for IBI363—melanoma, colorectal cancer(CRC), and non-small cell lung cancer (NSCLC)—have all been accepted for oral presentations, highlighting the significant attention garnered by the next-generation bispecific antibodies, in particular PD-1-based immunotherapy. Additionally, following its oral presentation at ESMO Asia last December, the Phase 1b data of IBI343 in pancreatic cancer has once again secured an oral presentation at ASCO, further solidifying its potential in this challenging therapeutic area. The maturing PoC data for these innovative candidates has strengthened our confidence in advancing them into pivotal-stage development, with the goal of unlocking their clinical value for global unmet clinical needs. As one of the few biopharmaceutical companies with both the advanced technology platforms and robust pipeline in \"IO+ADC\" areas, Innovent will continue to make breakthroughs in the field of cancer treatment, and is committed to providing physicians and patients with more innovative, effective and safe treatment options.\"\nDetails on the abstracts are listed below:\nOral Presentation\n1. Presentation Title: Efficacy and safety results of a first-in-class PD-1/IL-2 α-bias bispecific antibody fusion protein, IBI363, in patients with immunotherapy-treated, advanced acral and mucosal melanoma\nAbstract Number: 2502\nSession Type: Oral Abstract\nSession Title: Developmental Therapeutics-Immunotherapy\nSession Date & Time: 5/31/2025 3:00 PM-6:00 PM CDT\nPresenter: Jun Guo , MD, Beijing Cancer Hospital\n2. Presentation Title: Efficacy and safety of IBI363 monotherapy or in combination with bevacizumab in patients with advanced colorectal cancer\nAbstract Number: 104\nSession Type: Oral Abstract\nSession Title: Clinical Science Symposium—Turning \"Cold\" Tumors \"Hot\"\nSession Date & Time: 6/1/2025 9:45 AM-11:15 AM CDT\nPresenter: Zhenyu Lin , MD, Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology\n3. Presentation Title: First-in-class PD-1/IL-2 α-bias bispecific antibody, IBI363, in patients with advanced immunotherapy-treated non-small cell lung cancer (NSCLC)\nAbstract Number: 8509\nSession Type: Oral Abstract\nSession Title: Clinical Science Symposium—Two Targets, One Goal: The Potential for Bispecific Antibodies in Thoracic Malignancies\nSession Date & Time: 6/3/2025 9:45 AM-11:15 AM CDT\nPresenter: Jianya Zhou , MD, The First Affiliated Hospital, Zhejiang University School of Medicine\n4. Presentation Title: Claudin18.2 (CLDN18.2) expression and efficacy in pancreatic ductal adenocarcinoma (PDAC): results from a Phase 1 dose expansion cohort evaluating IBI343\nAbstract Number: 4017\nSession Type: Rapid Oral Abstract\nSession Title: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary\nSession Date & Time: 6/2/2025 11:30 AM-1:00 PM CDT\nPresenter: Xianjun Yu , MD, Fudan University Shanghai Cancer Center\n5. Presentation Title: Sintilimab (anti-PD-1) plus ifosfamide, carboplatin and etoposide (ICE) in second-line classical Hodgkin lymphoma (cHL): Results of a multicenter, randomized, controlled, double-blind Phase 3 study ( ORIENT -21)\nAbstract Number: 7007\nSession Type: Oral Abstract\nSession Title: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia\nSession Date & Time: 5/30/2025 2:45 PM-5:45 PM CDT\nPresenter: Peng Liu,MD, Cancer Hospital, Chinese Academy of Medical Sciences\n6. Presentation Title: Short-course radiotherapy followed by sintilimab and CAPOX as total neoadjuvant treatment in locally advanced rectal cancer: A prospective, randomized controlled trial (SPRING-01)\nAbstract Number: 3519\nSession Type: Rapid Oral Abstract\nSession Title: Gastrointestinal Cancer-Colorectal and Anal\nSession Date & Time: 6/1/2025 11:30 AM-1:00 PM CDT\nPresenter：Changqing Jing, MD, Shandong Provincial Hospital\n7. Presentation Title: Dynamic circulating tumor DNA-driven, risk-adapted systematic therapy in n as opharyngeal carcinoma: The EP-STAR trial\nAbstract Number: 6010\nSession Type: Oral Abstract\nSession Title: Clinical Science Symposium -Biomarker-Driven Adaptive Therapy: New Horizons in Head and Neck Cancer\nSession Date & Time: 6/2/2025 3:00 PM-4:30 PM CDT\nPresenter: Ying Sun , MD, Sun Yat -sen University Cancer Center\nPoster Presentation\n1. Presentation Title: A multicenter, randomized, controlled, open-label, Phase 2 study of the PD-1/IL-2 α-bias bispecific antibody fusion protein IBI363 in mucosal and acral melanoma: Trial in Progress\nAbstract Number: TPS9594\nSession Type: Poster\nSession Title: Melanoma/Skin Cancers\nSession Date & Time: 6/1/2025 9:00 AM-12:00 PM CDT\nPresenter: Bin Lian, MD, Peking University Cancer Hospital & Institute\n2. Presentation Title: IBI354, an anti-HER2 antibody-drug conjugate, in patients with locally advanced unresectable or metastatic ovarian cancers: updated results from a Phase 1 trial\nAbstract Number: 5565\nSession Type: Poster\nSession Title: Gynecologic Cancer\nSession Date & Time: 6/1/2025 9:00 AM-12:00 PM CDT\nPresenter: Jin Shu , MD, Chongqing University Cancer Hospital\n3. Presentation Title: IBI354 (anti-HER2 antibody-drug conjugate [ADC]) in patients with HER2-positive breast cancer (BC) and other solid tumors: Updates from a Phase 1 study\nAbstract Number: 1029\nSession Type: Poster\nSession Title: Breast Cancer—Metastatic\nSession Date & Time: 6/2/2025 9:00 AM-12:00 PM CDT\nPresenter: Charlotte Rose Lemech, BSc , FRACP, MBBS , Scientia Clinical Research\n4. Presentation Title: Safety and efficacy of the anti-TROP2 antibody-drug conjugate (ADC) IBI130 in patients with advanced triple-negative breast cancer (TNBC) and other solid tumors: Results from the Phase 1 study\nAbstract Number: 1102\nSession Type: Poster\nSession Title: Breast Cancer—Metastatic\nSession Date & Time: 6/2/2025 9:00 AM-12:00 PM CDT\nPresenter: Fan Wu , MD, Fujian Cancer Hospital\n5. Presentation Title: A multiregional, randomized, controlled, open-label, Phase 3 study of the anti-claudin18.2 (CLDN18.2) antibody-drug conjugate (ADC) arcotatug tavatecan (IBI343) in gastric or gastroesophageal junction adenocarcinoma (G/GEJA): Trial in Progress\nAbstract Number: TPS4201\nSession Type: Poster\nSession Title: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary\nSession Date & Time: 5/31/2025 9:00 AM-12:00 PM CDT\nPresenter: Lin Shen , MD, Beijing Cancer Hospital\n6. Presentation Title: Phase 2 trial of transarterial chemoembolization followed by sintilimab (anti-PD-1), oxaliplatin, and S-1 combined with either trastuzumab (HER-2 positive) or apatinib (HER-2 negative) as first-line therapy for gastric cancer with liver metastases.\nAbstract Number: 4050\nSession Type: Poster\nSession Title: Gastrointestinal Cancer-Gastroesophageal, Pancreatic, and Hepatobiliary\nSession Date & Time: 5/31/2025 9:00 AM-12:00 PM CDT\nPresenter: Dan Sha , MD, Shandong Provincial Hospital\n*Abstracts of TYVYT ® (sintilimab) are from investigator-initiated clinical trials (IIT), except one abstract, #7007.\nAbout Innovent\nInnovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 15 products in the market. It has 3 new drug applications under regulatory review, 4 assets in Phase III or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, Adimab, LG Chem and MD Anderson Cancer Center.\nGuided by the motto, \"Start with Integrity, Succeed through Action,\" Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com , or follow Innovent on Facebook and LinkedIn.\nStatement:\n(1) Innovent does not recommend the use of any unapproved drug (s)/indication (s).\n( 2) Ramucirumab (Cyramza) and Selpercatinib (Retsevmo) and Pirtobrutinib (Jaypirca) were developed by Eli Lilly and Company.\nForward-looking statement\nThis news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words \"anticipate\", \"believe\", \"estimate\", \"expect\", \"intend\" and similar expressions, as they relate to Innovent Biologics (\"Innovent\"), are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly.\nThese forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company's competitive environment and political, economic, legal and social conditions.\nThe Company, the Directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialise or turn out to be incorrect.\nView original content: https://www.prnewswire.com/apac/news-releases/seven-oral-presentations-innovent-to-present-breakthrough-clinical-data-of-ibi363pd-1il-2-biasand-other-novel-drug-candidates-at-the-2025-asco-annual-meeting-302436197.html\nSOURCE Innovent Biologics",
    "highlightText": "",
    "highlightTitle": "",
    "highlightThreadTitle": "",
    "language": "english",
    "sentiment": "positive",
    "categories": [
      "Health"
    ],
    "topics": [
      "Health->health treatment and procedure",
      "Health->medical specialisation",
      "Health->drug rehabilitation"
    ],
    "ai_allow": true,
    "has_canonical": false,
    "breaking": false,
    "webz_reporter": false,
    "external_links": [
      "http://www.innoventbio.com",
      "https://www.prnewswire.com/apac/news-releases/seven-oral-presentations-innovent-to-present-breakthrough-clinical-data-of-ibi363pd-1il-2-biasand-other-novel-drug-candidates-at-the-2025-asco-annual-meeting-302436197.html",
      "https://prnewswire.com/apac/news-releases/seven-oral-presentations-innovent-to-present-breakthrough-clinical-data-of-ibi363pd-1il-2-biasand-other-novel-drug-candidates-at-the-2025-asco-annual-meeting-302436197.html",
      "http://innoventbio.com"
    ],
    "entities": {
      "persons": [],
      "locations": [],
      "organizations": [
        {
          "name": "American Society of Clinical Oncology",
          "sentiment": "none",
          "tickers": []
        },
        {
          "name": "Innovent Biologics, Inc.",
          "sentiment": "none",
          "tickers": []
        },
        {
          "name": "Crypto ETP",
          "sentiment": "none",
          "tickers": []
        },
        {
          "name": "ASCO",
          "sentiment": "none",
          "tickers": []
        }
      ]
    },
    "syndication": {
      "syndicated": false,
      "syndicate_id": null,
      "first_syndicated": false
    },
    "trust": {
      "categories": [],
      "bias": null,
      "source": {
        "type": null,
        "city": null,
        "state": null,
        "country": null,
        "domain_type": null,
        "agency": null,
        "organization_name": null
      }
    },
    "rating": null,
    "crawled": "2025-04-24T02:14:41.046+03:00",
    "updated": "2025-04-24T02:14:41.046+03:00"
  }
]